GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Notes Receivable

Fennec Pharmaceuticals (TSX:FRX) Notes Receivable : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Notes Receivable?

Fennec Pharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2024 was C$0.00 Mil.


Fennec Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Fennec Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Notes Receivable Chart

Fennec Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fennec Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Fennec Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Chris Anigeron Rallis Director
Rostislav Christov Raykov Director, Senior Officer
Robert Christopher Andrade Senior Officer
Adrian J. Haigh Senior Officer
Khalid Islam Director

Fennec Pharmaceuticals Headlines

From GuruFocus

Forest Road Letter to Stockholders

By Business Wire Business Wire 06-01-2021

Beachbody CEO Letter to Forest Road Shareholders

By Business Wire Business Wire 06-09-2021